MONTREAL, Feb. 14, 2014 /CNW Telbec/ - In the presence of Quebec
Premier, Pauline Marois, ministers Nicolas Marceau, Jean-François Lisée
and Élaine Zakaïb, Montreal Mayor, Denis Coderre, and the
representatives of international pharmaceutical companies, Dr.
Jean-Claude Tardif, Director of the Research Centre of the Montreal
Heart Institute (MHI), announced today the launch of ARTERIA, a
research program aimed at developing ground-breaking treatments for
cardiovascular diseases, the number one cause of death worldwide. "Once
again, the Montreal Heart Institute and its team of dedicated
physicians, researchers and professionals have established themselves
as world leaders in the fight against heart disease. This program will
have tangible positive effects on patients living with or at risk of
developing cardiovascular disease," declared Dr. Tardif.
The discoveries and innovations that will stem from this unique program
will substantially benefit patients over the medium and long term by
transforming medical practices in the treatment of heart disease, all
while realizing major savings for the health system as a whole. Among
its many benefits, ARTERIA will make it possible to deliver
increasingly personalized medicine and to treat and medicate patients
more effectively, thus saving lives. It is noteworthy that
cardiovascular diseases are the leading cause of hospitalization and
deaths in the world, and that 1.3 million Canadians suffer from various
forms of the illness. Cardiovascular diseases also represent the
largest economic burden of all diagnostic categories with total annual
costs of approximately $22 billion in Canada.
Unprecedented partnership yields major investment of $49.2M
This monumental cutting-edge project has been made possible thanks to
the $49.2 million it has received in funding. Of this amount, $18.2M
has come from the Government of Quebec and $31M has come from private
investments linked to the biopharmaceutical sector. "We are very proud
at the Montreal Heart Institute Research Centre to have succeeded in
attracting to this research program such key stakeholders as the Quebec
Government, Université de Montréal, and the world's most innovative
pharmaceutical companies, so that our patients and all Quebecers may
benefit from the fruits of this important research," added Dr. Tardif.
ARTERIA will also lead to the creation of 150 new direct, high-skilled
On-hand at the announcement, the program's main private partners were
eager to praise the MHI Research Centre's initiative in establishing
this innovative project. In so doing, they attested to the Institute's
indisputable leadership on the world stage.
"Through our collaboration, we will be able to combine the MHI's
worldwide network of scientific and medical research with our
capabilities in translational medicine and clinical development. For
this reason, to Hoffmann-La Roche Ltd, the Montreal Heart Institute is
unequivocally a world-class Quebec institution," noted Ronnie Miller,
President and Chief Executive Officer of Hoffmann-La Roche Ltd. Canada.
Frédéric Fasano, Canadian CEO of major ARTERIA partner Servier Canada
Inc., for his part underscored the long-standing collaboration between
the two organizations: "Our collaboration with the Montreal Heart
Institute began over 15 years ago. It has been extremely productive in
terms of research and innovation, case in point being a medication to
treat patients with heart failure which was largely developed within
the walls of the Institute. To work with the Montreal Heart Institute
is to work alongside cardiologists and researchers of one of North
America's top cardiology centres."
Lastly, major partner MedImmune (a subsidiary of AstraZeneca) stressed
the uniqueness of the MHI and its model. "In taking part in the ARTERIA
program, AstraZeneca, like all other public and private partners and
all patients, will benefit from the internationally outstanding
facility that is the Montreal Heart Institute. The Institute is the
only one to offer an integrated model that runs the gamut from
genetics, to cellular analysis, to major clinical studies. The Montreal
Heart Institute is simply the only centre of its kind in the world,"
added Dr. Fouzia Laghrissi-Thode, Global Vice-President in charge of
AstraZeneca's Cardiovascular and Metabolic division.
Dr. Guy Breton, Rector of the Université de Montréal, to which MHI is
affiliated, was thrilled about the announcement. "We are very proud of
the three Université de Montréal research teams that received funding
as part of this new program. I especially congratulate Dr. Tardif and
his team at the Montreal Heart Institute who are set to lead a research
program that is innovative from every standpoint. On this Valentine's
Day, which calls to mind the importance of the heart, I am delighted to
know that researchers of such high calibre will have access to
resources and partners that will enable them to develop new avenues to
improve heart health.
The product of a vast and diversified partnership, ARTERIA has also been
made possible by the significant contribution and tangible support of
the following partners: Valeant Canada, Pharmascience Inc., Thrasos
Therapeutics Inc., Pfizer Canada Inc., Spartan Bioscience Inc., and the
Montreal Heart Institute Foundation.
To view the photo gallery: http://www.icm-mhi.org/fr/salle-presse/materiel-telecharger-et-contenu-multimedia/galerie-photos/conference-presse-projet-arteria
Founded by Dr. Paul David, The Montreal Health Institute is celebrating
its 60th anniversary in 2014. This commemorative year will be the
occasion to highlight the remarkable achievements in patient care,
research, prevention and teaching that have led the MHI to rise to the
ranks of the top cardiology centres in the world. Montreal-born and
internationally renowned, the Montreal Heart Institute has for the past
60 years brought together impassioned experts who are devoted to
pushing the boundaries of medicine in order to offer exceptional
About the Montreal Heart Institute: www.icm-mhi.org.
SOURCE: MONTREAL HEART INSTITUTE
For further information: